Clinical Trial Update: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nivolumab and ipilimumab with or without UV1 vaccination as second-line therapy for malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Mesothelioma
• Pleural Mesothelioma

Drugs mentioned

• UV1 vaccination (UV1 vaccine)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Åslaug Helland | Conditions: Cancer, Cancer, Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING